Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and counseling patients during eye exams.
Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
The risk for nonproliferative diabetic retinopathy progression was similar ... during a mean follow-up period of 8 months receiving treatment, the risk for incident NPDR did not differ across ...
Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase ... Opal platform to discover new therapeutic targets in ...
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
These fragile new vessels leak fluid that collects ... until significant damage occurs. What are the treatment options available for diabetic retinopathy? Early stages may only require ongoing ...
Patients with diabetic retinopathy need special care while pregnant, according to a speaker at Retina 2025. Irena Tsui, MD, said hormonal, metabolic and vascular changes during pregnancy can lead to ...
DR was graded according to early Treatment Diabetic Retinopathy (ETDRS) criteria. Results: Of 199 subjects, 108 patients (54.3%) suffer from dry eye syndrome. Although dry eye syndrome was more ...
Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...
Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback